Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.You may also be interested in...
Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: